Related Experiment Video
Updated: Jul 7, 2026
10:32
Development of a Virtual Reality Assessment of Everyday Living Skills
Published on: April 23, 2014
Antipsychotic safety and efficacy concerns.
1Department of Psychiatry, University of California, San Diego, CA 92161, USA. jmmeyer@ucsd.edu
The Journal of Clinical Psychiatry
|February 26, 2008
Summary
Atypical antipsychotics may not be superior to older drugs for schizophrenia treatment, as large trials like CATIE and CUtLASS 1 found limited evidence of improved safety or effectiveness. Long-term studies are needed to fully assess benefits and risks.
Area of Science:
- Psychiatry and Pharmacology
- Clinical Trials and Evidence-Based Medicine
Background:
- Schizophrenia treatment has shifted towards atypical antipsychotics, replacing first-generation agents.
- Clinicians and researchers question the proven superiority of atypical antipsychotics in terms of safety and efficacy.
- Existing trials like CATIE and CUtLASS 1 did not conclusively demonstrate the expected advantages of atypical antipsychotics over typical ones.
Purpose of the Study:
- To evaluate the comparative safety and effectiveness of atypical versus typical antipsychotic medications for schizophrenia.
- To determine if specific atypical antipsychotics offer advantages over others.
- To assess if longer study durations are necessary to detect potential long-term benefits of atypical antipsychotics.
Main Methods:
- Review and analysis of evidence from major clinical trials, including the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and the Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
- Comparison of outcomes between atypical and typical antipsychotic treatment groups.
- Consideration of study duration in relation to potential long-term treatment effects.
Main Results:
- The CATIE and CUtLASS 1 trials did not provide compelling evidence supporting the superiority of atypical antipsychotics over typical ones in terms of safety or effectiveness.
- While atypical antipsychotics show lower rates of extrapyramidal symptoms, concerns have shifted to metabolic side effects.
- The duration of existing trials may have been insufficient to capture long-term differences between drug classes.
Conclusions:
- Current evidence does not definitively establish the superiority of atypical antipsychotics for schizophrenia treatment.
- Longer-term studies are recommended to ascertain the full benefits and risks, particularly regarding relapse prevention and long-term safety.
- Monitoring metabolic side effects has become a critical aspect of standard care for patients on atypical antipsychotics.
Related Concept Videos
01:21Antipsychotic Drugs: Therapeutic Uses and Side Effects
Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
01:28Psychosis and Antipsychotic Drugs: Overview
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic symptoms in all...
01:26Psychosis: Goals of Pharmacotherapy
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
01:21Antipsychotic Drugs: Typical and Atypical Agents
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
01:27Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within the...
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within the...